



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/083,288	02/26/2002	Anthony C. Vrba	1001.1541101	4123	
28075	7590 02/10/2005		EXAMINER		
	N, SEAGER & TUF LLET AVENUE	SZMAL, BRI	SZMAL, BRIAN SCOTT		
SUITE 800	LEI AVENUE	ART UNIT	PAPER NUMBER		
MINNEAPC	LIS, MN 55403-2420	3736			

DATE MAILED: 02/10/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

-	·	Application	No.	Applicant(s)			
Office Action Summary		10/083,288		VRBA ET AL.			
		Examiner		Art Unit			
		Brian Szma	I	3736			
	The MAILING DATE of this communication	n appears on the c	over sheet with the c	orrespondence ad	ldress		
Period fo	• •						
THE I - Exter after - If the - If NO - Failui Any r	ORTENED STATUTORY PERIOD FOR RIMAILING DATE OF THIS COMMUNICATION Is ions of time may be available under the provisions of 37 Clostx (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days, period for reply is specified above, the maximum statutory per to reply within the set or extended period for reply will, by seply received by the Office later than three months after the department of the provided patent term adjustment. See 37 CFR 1.704(b).	ON. FR 1.136(a). In no event on. a reply within the statuto period will apply and will e statute, cause the applica	, however, may a reply be tim ry minimum of thirty (30) days xpire SIX (6) MONTHS from tion to become ABANDONEI	nely filed s will be considered timel the mailing date of this or D (35 U.S.C. § 133).	y. ommunication.		
Status							
1) 🛛	Responsive to communication(s) filed on	29 November 200	14 .				
·		This action is nor					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
5)□ 6)⊠ 7)□	Claim(s) <u>1-26</u> is/are pending in the applicated 4a) Of the above claim(s) is/are with Claim(s) is/are allowed. Claim(s) <u>1-26</u> is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction a	hdrawn from cons					
Applicati	on Papers				}		
9)[The specification is objected to by the Exa	miner.					
10) 🗌	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	ınder 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachmen	t(s)						
1) Notice 2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-94 mation Disclosure Statement(s) (PTO-1449 or PTO/S r No(s)/Mail Date	(8) SB/08)	Interview Summary Paper No(s)/Mail Do Notice of Informal Po Other:	ate	O-152)		

Application/Control Number: 10/083,288 Page 2

Art Unit: 3736

Claim Objections

1. Claim 16 is objected to because of the following informalities: The claim contains a registered trademark of DuPont, "Dacron", which cannot be claimed. Appropriate correction is required.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 3. Claims 1-10 and 17-22 are rejected under 35 U.S.C. 102(e) as being anticipated by Levinson et al (6,277,139).

Levinson et al disclose a vascular protection and embolic material retriever and further disclose an elongated core wire having a longitudinal axis, a proximal end and a distal end; an actuatable stop (20) disposed at the distal end of the core wire, the actuatable stop (20) moveable between a collapsed position and an expanded position; an actuator couple to the stop (20), the actuator moveable between a first position and a second position to move the stop (20) between the collapsed position and the expanded position; a filter disposed on the core wire; the actuatable stop (20) comprises a tubular member having a proximal end and a distal end; the distal section of said tubular

Application/Control Number: 10/083,288 Page 3

Art Unit: 3736

member includes a plurality of circumferentially disposed openings adapted to permit a plurality of struts disposed therebetween to expand in an outward direction; the inner diameter of the tubular member is substantially similar to the outer diameter of the core wire; the inner diameter of the tubular member is larger than the outer diameter of the core wire; a locking mechanism adapted to prevent relative motion between the actuatable stop (20) and the core wire; the locking mechanism comprises an enlarged outer diameter portion disposed on the core wire; the locking mechanism comprises an enlarged outer diameter portion disposed on the core wire corresponding in size and shape to a reduced inner diameter portion disposed on the actuatable stop (20); the locking mechanism comprises a locking hub disposed about a proximal portion of the core wire; and an actuator disposable about the core wire, the actuator having a proximal end and a distal end. See Column 6, lines 21-37; Column 7, lines 31-67; Column 9, lines 47-53; Column 12-20; Column 12, lines 48-51; and Column 13, lines 33-36.

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

5. Claims 13, 15 and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Levinson et al (6,277,139) as applied to claim 10 above, and further in view of Dubrul et al (6,602,265).

Levinson et al, as discussed above, disclose a vascular protection and embolic material remover but fail to disclose the actuatable stop comprises a polymeric tube; the actuateable stop comprises a mesh sleeve; and the mesh sleeve comprises Dacron. Dubrul et al, as discussed above disclose an intravascular tissue separation device and further disclose the actuatable stop comprises a polymeric tube; the actuateable stop comprises a mesh sleeve; and the mesh sleeve comprises Dacron. See Column 7, lines 15-23 and 51-67; Column 8, lines 13-15; and Column 14, lines 1-8 and 44-54. Since both Levinson et al and Dubrul et al disclose intravascular devices that remove material, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of Levinson et al to include the use of a polymeric tube or a polymeric mesh sleeve, as per the teachings of Dubrul et al, since it is well known in the art to utilize many biocompatible materials on intravascular devices, including metals as well as polymeric materials.

6. Claims 11, 12 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Levinson et al (6,277,139) as applied to claim 10 above, and further in view of Tate (3,841,308).

Levinson et al, as discussed above, disclose a vascular protection and embolic material retriever but fail to disclose the actuatable stop comprising a spring coil; a spring coil helically disposed about the core wire; and the polymeric tube is accordion-shaped.

Tate discloses a distally valved catheter device and further discloses the actuatable stop comprising a spring coil; a spring coil helically disposed about the core wire; and the polymeric tube is accordion-shaped. See Figures 2, 4 and 6-8.

Since both Levinson et al and Tate disclose catheter devices, it would have been obvious to one of ordinary skill in the art to modify the device of Levinson et al to include the use of a spring coil and have the polymeric tube be accordion-shaped, as per the teachings of Tate, since it is well known to provide a helical coil about the distal end of a guidewire device as well as a polymeric tube that has the ability to be accordion-shaped.

7. Claims 23-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cohen et al (5,167,239) in view of Dubrul et al (6,602,256 B2).

Cohen et al disclose an anchorable guidewire and further disclose advancing a catheter along the guidewire; providing an articulating guidewire comprising an elongated core wire having a longitudinal axis, a proximal end and a distal end; and an actuatable stop disposed at the distal end of the core wire, said actuatable stop moveable between a collapsed position and an expanded position; inserting the guidewire into the lumen of a blood vessel; positioning a distal portion of the guidewire beyond a lesion or other protrusion within the body; and actuating the actuatable stop from the collapsed position to the expanded position. See Column 3, lines 64-68; Column 14, lines 31-68; and Column 15, lines 1-8.

Cohen et al however fail to disclose advancing a filter on the guidewire; and advancing an intravascular device along the core wire until the intravascular device abuts the outwardly expanded stop.

Dubrul et al disclose a vascular protection and embolic material retriever placed over a guidewire and further disclose advancing a filter on the guidewire; and advancing an intravascular device along the core wire until the intravascular device abuts the outwardly expanded stop. See Column 6, lines 63-64; Column 7, lines 15-23 and 51-67; Column 8, lines 13-15; and Column 14, lines 1-8 and 44-54.

Since both Cohen et al and Dubrul et al disclose the advancement of catheters along a guidewire, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the method of Cohen et al to include the use of a filter, as per the teachings of Dubrul et al, since it would provide a means of trapping and removing material from within the lumen.

Response to Arguments

- 8. Applicant's arguments with respect to claims 23-26 have been considered but are most in view of the new ground(s) of rejection.
- 9. Applicant's arguments filed November 29, 2004 have been fully considered but they are not persuasive. Regarding claim 16, the use of Dacron remains objected due to the fact that Dacron is a registered trademark of the DuPont corporation. Dacron is not considered a "name used in the trade" as disclosed in the MPEP § 608.01(v). The fact that the Applicant found 256 patents with Dacron in at least one claim is irrelevant, due

to the fact that the MPEP prohibits the claiming of registered trademarks. The objection will stand until the claim is cancelled or Dacron is replaced with a generic name.

The Examiner respectfully traverses the argument of Levinson et al not teaching all of the claimed elements. Per the current disclosure, a stop is moveable between a collapsed position and an expanded position. In Levinson et al, the expandable frame (20) acts in a similar manner to that of the claimed stop, wherein the frame is moveable between a collapsed position and an expanded position. Therefore, Levinson et al clearly discloses an actuateable stop (20), per the current claim language and disclosure.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Szmal whose telephone number is (571) 272-4733. The examiner can normally be reached on Monday-Friday, with second Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Max Hindenburg can be reached on (571) 272-4726. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/083,288

Art Unit: 3736

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

BS

MAX F. HINDENBURG SUPERMSORY PATENT EXAMINER TECHNOLOGY CENTER 3700

Page 8